Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

2.610 +0.150 (+6.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,789,974
Open 2.420
Bid (Size) 2.580 (11)
Ask (Size) 2.650 (4)
Prev. Close 2.460
Today's Range 2.405 - 2.625
52wk Range 1.990 - 11.59
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Expert Ratings for Nektar Therapeutics
Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
+19.18%
+19.18%
1 Month
+18.64%
+18.64%
3 Month
-30.59%
-30.59%
6 Month
-30.77%
-30.77%
1 Year
-75.49%
-75.49%

More News

Read More
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'
Via Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
Via Benzinga
PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Recap: Nektar Therapeutics Q2 Earnings
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Nektar Shares Are Down Almost 35%
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.